Biosimilars Rising: The Catalyst for a New Age in Biologics Therapies
Insights Details
Month: Mar 26
Tags: Biosimilars, Biologic Therapies, Biosimilar 2.0, Golden Decade of Biosimilars, Market Access, Patent Cliff, Oncology Biosimilars, Immunology Biosimilars, Ophthalmology Biosimilars, GLP‑1 Biosimilars, Rare Disease Biosimilars, FDA Biosimilar Guidance, EMA Biosimilar Framework, Interchangeability, Healthcare Cost Savings, Specialty Pharmacy, Biopharma Strategy, Sandoz Biosimilars, APAC Biosimilar Hub, India Biosimilars Market
Let’s Work Together for Development
Call us directly, submit a sample or email us!
About topic:
This video explores how biosimilars are reshaping the global biologics landscape, moving beyond cost savings to become strategic drivers of specialty care, affordability, and patient access. It highlights the emergence of a “Golden Decade of Biosimilars,” fueled by patent expiries, evolving regulatory pathways across the US, EU, India, and APAC, and advances in technology.
The video introduces “Biosimilar 2.0,” where AI-driven bioprocessing, advanced analytics, and streamlined regulations are accelerating development and commercialization. As a result, biosimilars are positioned to unlock a ~$190-200B market by the mid-2030s while expanding access across key therapeutic areas such as oncology, immunology, diabetes, ophthalmology, neurology, and rare diseases.
Overall, biosimilars are no longer just alternatives they are becoming the backbone of sustainable specialty care and a key force redefining the future of biologic therapies globally.
Biosimilars Rising: The Catalyst for a New Age in Biologics Therapies
Highlights:
Babli Singh is a Senior Analyst with strong analytical skills and a deep understanding of the biopharmaceutical and healthcare industries. She specializes in monitoring emerging trends and distilling complex information into concise, insightful summaries that deliver clear value and actionable intelligence for a global professional audience.
